PUNE, India, Oct. 04, 2022 (GLOBE NEWSWIRE) — The Home Infusion Therapy Market in the United States The size was $16.21 billion in 2020. The market value is projected to increase from US$13.05 billion in 2021 to US$21.65 billion in 2028 at a CAGR of 7.5% over the forecast period. The rise in home health care and expansion of home infusion therapy services in the US should drive growth. The high percentage of geriatric people in the country will continue to fuel the trend of home health care in the years to come. Fortune Business Insights presents this information in its report titled “US Home Infusion Therapy Market, 2021-2028.”
Home infusion therapy refers to the intravenous administration of biologics or drugs to a patient’s home. Its acceptance has increased significantly in recent years due to the increase in healthcare outside of the hospital setting. Factors such as the aging population and increasing prevalence of chronic diseases are the main factors driving the shift towards home healthcare. Other factors include the ongoing pressure to reduce costs by reducing healthcare-associated infections (HAIs) and reducing hospital stays.
Notable industry developments:
July 2021 – Baxter International Inc. and Micrel Medical signed an agreement to distribute the Micrel Mini Rythmic PN+ infusion pump.
Request a sample copy of the research report
Report scope and segmentation
| report coverage | details |
| forecast period | 2021 to 2028 |
| Forecast period 2021 to 2028 CAGR | 7.5% |
| Value prognosis 2028 | $21.65 billion |
| base year | 2020 |
| Market size in 2020 | $16.21 billion |
| Historical data for | 2017 to 2019 |
| number of pages | 74 |
| Important market participants | Option Care Health Inc. (Illinois, USA), Optum, Inc. (Eden Prairie, USA), CareCentrix, Inc. (Hartford, USA), CVS Health (Woonsocket, Rhode Island, USA), KabaFusion (Cerritos, USA) |
| Market growth in the US for home infusion therapy … |
